Bionure logo

Bionure

Clinical stage biotech developing new drugs for CNS diseases.

8 employees · est. 2009 · Barcelona, Spain

VS
GenSight Biologics logo

GenSight Biologics

Applying pathbreaking science to transform the lives of patients with severe retinal neurodegenerative diseases

34 employees · est. 2013 · Paris, France

Bionure is the older company (2009 vs 2013); GenSight Biologics is the larger of the two.

Side-by-Side Comparison

Bionure GenSight Biologics
Founded
2009 older 2013
Headquarters
Barcelona, Spain Paris, France
Employees
8 34 larger
Industry
Biotechnology, Health Care, Medical Devices Biotechnology, Health Care
Funding Stage
Series A Post Ipo Equity
Total Funding
$5.07M $245.64M
Funding Rounds
3 17
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Biotech, Neurodegenerative Diseases, Clinical Stage, Drug Development, Neuroprotection, Remyelination, Orphan Designation, Ophthalmology, Rare Diseases, SGK Agonists, Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis, Neuro-inflammation, Clinical Trials Clinical-stage Biotech, Gene Therapy, Retinal Diseases, Neurodegenerative Diseases, Mitochondrial Targeting Sequence, Optogenetics, Retinitis Pigmentosa, LHON, Gene Therapy-Based Treatments, Intravitreal Injection, Vision Restoration, Retinal Degeneration, Rare Diseases, Innovative Therapies
Website
bionure.com gensight-biologics.com
Bionure logo

About Bionure

Bionure is a clinical-stage biotech company focused on developing therapies for neurodegenerative diseases that currently lack treatment options. The company's lead candidate, BN201, is a first-in-class small molecule drug that has shown promising results in promoting neuroprotection and remyelinati...

GenSight Biologics logo

About GenSight Biologics

GenSight Biologics is a biotechnology startup focused on developing groundbreaking therapies for severe retinal neurodegenerative diseases. Leveraging the Mitochondrial Targeting Sequence (MTS) and optogenetics, the company is striving to preserve or restore vision in patients with degenerative reti...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at Bionure and GenSight Biologics — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at Bionure and GenSight Biologics — by email.

Frequently Asked Questions

Bionure — Clinical stage biotech developing new drugs for CNS diseases. . GenSight Biologics — Applying pathbreaking science to transform the lives of patients with severe retinal neurodegenerative diseases. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Bionure has raised $5.07M while GenSight Biologics has raised $245.64M.
Bionure and GenSight Biologics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Bionure with someone else

Start typing a company name or domain.

One analytics cookie (Google Analytics). Cookie Policy